PTCT
PTC Therapeutics, Inc. · Healthcare · Biotechnology
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 2 | 0 | 18.67K | $1.18M | n/a | n/a |
| Q2 2026 | 115 | +8 | 59.02M | $4.80B | +13 | −5 |
| Q1 2026 | 110 | -8 | 65.31M | $4.45B | +9 | −18 |
| Q4 2025 | 117 | 0 | 67.93M | $5.16B | +1 | n/a |
| Q3 2025 | 22 | +2 | 38.04M | $2.33B | +2 | n/a |
| Q2 2025 | 17 | 0 | 34.63M | $1.69B | +1 | −1 |
| Q1 2025 | 14 | +2 | 16.93M | $862.87M | +2 | n/a |
| Q4 2024 | 12 | 0 | 14.84M | $670.12M | n/a | n/a |
| Q3 2024 | 11 | -2 | 14.00M | $519.42M | n/a | −2 |
| Q2 2024 | 13 | n/a | 14.28M | $436.54M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wellington Management ✦ | 8.21M | n/a | $251.02M | 0.0% | n/c | 1 | SEC ↗ ×7 |
| 2 | Geode Capital Management ✦ (passive) | 1.79M | n/a | $54.68M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 3 | D. E. Shaw & Co. ✦ | 1.36M | n/a | $41.52M | 0.1% | n/c | 1 | SEC ↗ ×3 |
| 4 | Renaissance Technologies ✦ | 818.10K | n/a | $25.02M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | T. Rowe Price ✦ | 606.68K | n/a | $18.55M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 6 | Two Sigma Investments ✦ | 318.17K | n/a | $9.73M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | Millennium Management ✦ | 317.58K | n/a | $9.71M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Adage Capital Partners ✦ | 300.00K | n/a | $9.17M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | Citadel Advisors ✦ | 270.08K | n/a | $8.26M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 10 | Marshall Wace ✦ | 179.68K | n/a | $5.49M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 11 | AQR Capital Management ✦ | 68.91K | n/a | $2.11M | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 12 | Point72 Asset Management ✦ | 26.70K | n/a | $816,486 | 0.0% | n/c | 1 | SEC ↗ |
| 13 | Norges Bank ✦ (passive) | 15.10K | n/a | $461,758 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 348 holders, 95.15M shares, $6.33B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 382 sh · $22,973
Director · 2.12K sh · $126,063
Officer · 192 sh · $12,338
Director · 2.45K sh · $155,091
Director · 53 sh · $3,389
Officer · 435 sh · $27,910
Officer · 1.64K sh · $104,881
Director · 376 sh · $25,737
Director · 9.62K sh · $652,796
Director · 7.01K sh · $471,854
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology